tradingkey.logo

Guardant Health rises after Q4 revenue surpasses estimate

ReutersJan 12, 2026 12:15 PM

Medical diagnostics co Guardant Health GH.O shares rise 2% to $112.35 premarket

Co reports preliminary Q4 revenue of $280 mln vs analysts' average estimate of $268 mln, according to data compiled by LSEG

Attributes performance to year-on-year surge in oncology testing volumes by 38%

Co also attributes performance to wider adoption of its Smart Liquid Biopsy platform

Volumes for co's blood-based cancer screening test, Shield, increase nearly six times

GH stock more than tripled over past year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI